Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-analysis

Fetal Diagnosis and Therapy

Volumn 31, Issue 3, 2012, Pages 141-146

  Roberge, Stéphanie ^a   Villa, Pia ^b   Nicolaides, Kypros ^d   Giguére, Yves ^a   Vainio, Merja ^c   Bakthi, Abdelouahab ^e   Ebrashy, Alaa ^f   Bujold, Emmanuel ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF HELSINKI   (Finland)

^c KANTA HÄME CENTRAL HOSPITAL   (Finland)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e Centre Hospitalo universitaire de Blida   (Algeria)

^f CAIRO UNIVERSITY   (Egypt)

Author keywords

Aspirin; Preeclampsia; Preterm

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; PLACEBO;

DRUG EFFECT; GESTATIONAL AGE; HUMAN; HYPERTENSION; LABOR; LOW DRUG DOSE; META ANALYSIS; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TERM BIRTH;

ASPIRIN; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; ODDS RATIO; PLACENTATION; PRE-ECLAMPSIA; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860323582     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000336662     Document Type: Review

References (35)

1. Geographic variation in the incidence of hypertension in pregnancy: World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol 1988; 158: 80-83.
2. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137.
3. Witlin AG, Saade GR, Mattar F, Sibai BM: Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol 2000; 182: 607-611. (Pubitemid 30207320)
4. Irgens HU, Reisaeter L, Irgens LM, Lie RT: Long-term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001; 323: 1213-1217.
5. Von Dadelszen P, Magee L, Krajden M, Alasaly K, Popovska V, Devarakonda R, Money D, Patrick D, Brunham R: Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset pre-eclampsia. BJOG 2003; 110: 725-730. (Pubitemid 36936773)
6. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B: The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003; 189: 1173-1177. (Pubitemid 37373917)
7. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD: Morphometric placental villous and vascular abnormalities in early-and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 2006; 113: 580-589.
8. Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH: Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008; 31: 310-313.
9. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS: Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 2011; 39: 641-652.
10. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA: Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-1798. (Pubitemid 46782996)
11. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414.
12. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
13. Higgins J, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011.
14. ACOG: Diagnosis and management of preeclampsia and eclampsia. Int J Gynecol Obstet 2002; 77: 67-75.
15. Magee LA, Helewa M, Moutquin JM, von Dadelszen P: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30(suppl):S1-S48.
16. Sibai BM: Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 2011; 205: 191-198.
17. DerSimonian R, Laird N: Meta-Analysis in Clinical Trials. Controlled Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
18. Chevalier PVDM, Vermeire E: Hétérogénité dans les synthèses méthodiques et métaanalyses. Minerva 2007; 6: 160.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. (Pubitemid 37088507)
20. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
21. August P, Helseth G, Edersheim T, Hutson J, Druzin M: Sustained release, low-dose aspirin ameliorates but does not prevent preeclampsia in a high risk population. Proceedings of 9th International Congress of the International Society for the Study of Hypertension, 1994. Sydney, Hypertension in Pregnancy, 1994, p 72.
22. Bakhti A, Vaiman D: Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertens Res 2011; 34: 1116-1120.
23. Ebrashy A, Ibrahim M, Marzook A, Yousef D: Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J 2005; 46: 826-831. (Pubitemid 41414905)
24. Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J: Low-dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002; 109: 161-167. (Pubitemid 37338037)
25. Villa P, Taipale P, Räikkönen K, Hämäläinen E, Pesonen A, Kajantie E, Laivuori H: PREDO trial-acetylsalicylic acid in preventing pre-eclampsia in high-risk women. 17th ISSHP World Congress, Melbourne, October 2010. Pregnancy Hypertension 2010(suppl):1-41.
26. Beaufils M, Uzan S, Donsimoni R, Colau JC: Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985; 1: 840-842. (Pubitemid 15115117)
27. Sebire NJ, Goldin RD, Regan L: Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol 2005; 25: 117-118. (Pubitemid 43323022)
28. Vatten LJ, Skjaerven R: Is pre-eclampsia more than one disease? BJOG 2004; 111: 298-302. (Pubitemid 38446102)
29. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD: Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol 2002; 155: 203-209. (Pubitemid 34117298)
30. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R: Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950-955.
31. Xiao R, Sorensen TK, Williams MA, Luthy DA: Influence of pre-eclampsia on fetal growth. J Matern Fetal Neonatal Med 2003; 13: 157-162. (Pubitemid 36384515)
32. Staboulidou I, Galindo A, Maiz N, Karagiannis G, Nicolaides KH: First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects. Fetal Diagn Ther 2009; 25: 336-339.
33. Bujold E, Tapp S, Audibert F, Ferreira E, Forest JC, Rey E, Fraser WD, Chaillet N, Giguere Y: Prevention of adverse pregnancy outcomes with low-dose ASA in early pregnancy: new perspectives for future randomized trials. J Obstet Gynaecol Can 2011; 33: 480-483.
34. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
35. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.